GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » Net Income Including Noncontrolling Interests

Alterity Therapeutics (Alterity Therapeutics) Net Income Including Noncontrolling Interests : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Alterity Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Sep. 2023 was $0.00 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Alterity Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Alterity Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Net Income Including Noncontrolling Interests Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.57 -9.29 -11.70 -9.03 -9.27

Alterity Therapeutics Quarterly Data
Dec17 Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alterity Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Alterity Therapeutics (Alterity Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ASX:LTP ASX:CHM ASX:CYP ASX:IMC ASX:EZZ ASX:RAD ASX:PTX ASX:NOX ASX:PAB ASX:ACR OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
PBN:Germany ATH:Australia
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Website
https://www.alteritytherapeutics.com
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.